{"id":775602,"date":"2023-08-04T12:53:41","date_gmt":"2023-08-04T16:53:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/"},"modified":"2023-08-04T12:53:41","modified_gmt":"2023-08-04T16:53:41","slug":"medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/","title":{"rendered":"Medicenna Therapeutics to Provide Clinical Update from Phase 1\/2 ABILITY Study on August 9, 2023"},"content":{"rendered":"
\n

TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today that it will host a conference call and live webcast on August 9, 2023 at 8:30AM ET to provide a clinical update from the Phase 1\/2 ABILITY study evaluating MDNA11 in patients with melanoma and other select tumors.<\/p>\n

Shareholders and financial analysts are invited to join the live audio webcast either by phone or through the webcast link. Both options to connect to the webcast are described on Medicenna\u2019s website: https:\/\/ir.medicenna.com\/news-and-events\/events-and-presentations<\/a><\/p>\n

The webcast will be recorded and will then be available on Medicenna\u2019s website following the call.<\/p>\n

\n About Medicenna<\/strong>
\n
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna\u2019s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna\u2019s early-stage BiSKITs\u2122 program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically \u201ccold\u201d tumors. Medicenna\u2019s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA\/EMA, respectively.<\/p>\n


\n
\n \n <\/div>\n

\n
Further Information\r\n\r\nFor further information about the Company please contact:\r\n\r\nElizabeth Williams, Chief Financial Officer, ewilliams@medicenna.com\r\n\r\nDelphine Davan, Vice President, Investor Relations and Corporate Communications, ddavan@medicenna.com\r\n\r\nMedia Contact\r\n\r\nFor media inquiries, please contact:\r\n\r\nTony Russo,\u00a0Russo Partners, 212-845-4251,\u00a0tony.russo@russopartnersllc.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today that it will host a conference call and live webcast on August 9, 2023 at 8:30AM ET to provide a clinical update from the Phase 1\/2 ABILITY study evaluating MDNA11 in patients with melanoma and other select tumors. Shareholders and financial analysts are invited to join the live audio webcast either by phone or through the webcast link. Both options to connect to the webcast are described on Medicenna\u2019s website: https:\/\/ir.medicenna.com\/news-and-events\/events-and-presentations The webcast will be recorded and will then be available on Medicenna\u2019s website following the call. About Medicenna Medicenna is a clinical stage … <\/p>\n
Continue reading “Medicenna Therapeutics to Provide Clinical Update from Phase 1\/2 ABILITY Study on August 9, 2023”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-775602","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMedicenna Therapeutics to Provide Clinical Update from Phase 1\/2 ABILITY Study on August 9, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medicenna Therapeutics to Provide Clinical Update from Phase 1\/2 ABILITY Study on August 9, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today that it will host a conference call and live webcast on August 9, 2023 at 8:30AM ET to provide a clinical update from the Phase 1\/2 ABILITY study evaluating MDNA11 in patients with melanoma and other select tumors. Shareholders and financial analysts are invited to join the live audio webcast either by phone or through the webcast link. Both options to connect to the webcast are described on Medicenna\u2019s website: https:\/\/ir.medicenna.com\/news-and-events\/events-and-presentations The webcast will be recorded and will then be available on Medicenna\u2019s website following the call. About Medicenna Medicenna is a clinical stage … Continue reading "Medicenna Therapeutics to Provide Clinical Update from Phase 1\/2 ABILITY Study on August 9, 2023"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-04T16:53:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NzU1OCM1NzM3NzkxIzIxMjI0ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Medicenna Therapeutics to Provide Clinical Update from Phase 1\\\/2 ABILITY Study on August 9, 2023\",\"datePublished\":\"2023-08-04T16:53:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\\\/\"},\"wordCount\":259,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4NzU1OCM1NzM3NzkxIzIxMjI0ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\\\/\",\"name\":\"Medicenna Therapeutics to Provide Clinical Update from Phase 1\\\/2 ABILITY Study on August 9, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4NzU1OCM1NzM3NzkxIzIxMjI0ODE=\",\"datePublished\":\"2023-08-04T16:53:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4NzU1OCM1NzM3NzkxIzIxMjI0ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4NzU1OCM1NzM3NzkxIzIxMjI0ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medicenna Therapeutics to Provide Clinical Update from Phase 1\\\/2 ABILITY Study on August 9, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medicenna Therapeutics to Provide Clinical Update from Phase 1\/2 ABILITY Study on August 9, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/","og_locale":"en_US","og_type":"article","og_title":"Medicenna Therapeutics to Provide Clinical Update from Phase 1\/2 ABILITY Study on August 9, 2023 - Market Newsdesk","og_description":"TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today that it will host a conference call and live webcast on August 9, 2023 at 8:30AM ET to provide a clinical update from the Phase 1\/2 ABILITY study evaluating MDNA11 in patients with melanoma and other select tumors. Shareholders and financial analysts are invited to join the live audio webcast either by phone or through the webcast link. Both options to connect to the webcast are described on Medicenna\u2019s website: https:\/\/ir.medicenna.com\/news-and-events\/events-and-presentations The webcast will be recorded and will then be available on Medicenna\u2019s website following the call. About Medicenna Medicenna is a clinical stage … Continue reading \"Medicenna Therapeutics to Provide Clinical Update from Phase 1\/2 ABILITY Study on August 9, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-04T16:53:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NzU1OCM1NzM3NzkxIzIxMjI0ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Medicenna Therapeutics to Provide Clinical Update from Phase 1\/2 ABILITY Study on August 9, 2023","datePublished":"2023-08-04T16:53:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/"},"wordCount":259,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NzU1OCM1NzM3NzkxIzIxMjI0ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/","name":"Medicenna Therapeutics to Provide Clinical Update from Phase 1\/2 ABILITY Study on August 9, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NzU1OCM1NzM3NzkxIzIxMjI0ODE=","datePublished":"2023-08-04T16:53:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NzU1OCM1NzM3NzkxIzIxMjI0ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NzU1OCM1NzM3NzkxIzIxMjI0ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-provide-clinical-update-from-phase-1-2-ability-study-on-august-9-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Medicenna Therapeutics to Provide Clinical Update from Phase 1\/2 ABILITY Study on August 9, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/775602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=775602"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/775602\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=775602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=775602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=775602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}